BridgeBio plans U.S. launches of BBP-418, encaleret by 2027
BridgeBio Pharma said it will launch BBP-418, encaleret and infigratinib in the U.S. by 2027, while analysts including Leerink and Stifel trimmed BBIO price targets.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.